Rivastigmine in Focus: A Key Player in Alzheimer Disease Management

Alzheimer’s disease is a type of dementia commonly affecting older people. It is a age related neurodegenerative disorder characterized by multiple cognitive deficiencies which include memory loss, comprehensive. It causes mood disturbances and behavioral changes. 54% of dementia cases are believed to be due to Alzheimer disease in European union. There is no medicine discovered for Alzheimer’s but symptomatic therapies are widely available now. One of them is the therapy using Rivastigmine, it comes under the class of acetylcholinesterase inhibitors. Comparative analysis with other Cholinestrase inhibitors sheds light on the unique attributes of Rivastigmine. In this review Article we will be discussing about its background and history, pharmacokinetics and pharmacological parameters, physicochemical properties, method of synthesis, drug - drug interactions Special populations and many more.